Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 811 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle / Placebo Clear all
Completed Phase 2 Interventional

Lactobacillus Johnsonii Supplementation in Adults With T1D

NCT03961347
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
L. johnsonii Probiotic, Placebo Capsule
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

NCT02616614
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Onexton, Clindamycin/benzoyl peroxide gel, Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
862 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Phoenix, Arizona • Chula Vista, California • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 27, 2026, 4:35 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy

NCT07287033
View directory record Official record
Conditions
Peanut Allergies
Interventions
MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle)
Drug
Lead sponsor
Mabylon AG
Industry
Eligibility
12 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

NCT04089735
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, APP13007, 0.1%, APP13007 Placebo, 0.05%, APP13007 Placebo, 0.1%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Inglewood, California • Rancho Cordova, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 27, 2026, 4:35 PM EDT
Recruiting Phase 2 Interventional

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

NCT05639933
View directory record Official record
Conditions
Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
Interventions
HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo
Drug
Lead sponsor
Hoth Therapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Irvine, California • Orange, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

NCT02324270
View directory record Official record
Conditions
Ankle Sprain
Interventions
Diclofenac epolamine, Placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
658 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
31
States / cities
Birmingham, Alabama • Goodyear, Arizona • Carlsbad, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

NCT06050122
View directory record Official record
Conditions
Gorlin Syndrome
Interventions
Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Rogers, Arkansas • Fremont, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 on Gingival Mucosal Tissue in Normal Volunteers

NCT03233737
View directory record Official record
Conditions
No Disease State or Condition
Interventions
One spray CTY-5339-A, One spray CTY-5339-CB, One spray CTY-5339-P
Combination Product · Device
Lead sponsor
Cetylite Industries
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

NCT02235272
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
XG-102, Placebo
Drug
Lead sponsor
Xigen SA
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

NCT02014376
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
6 Months and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

NCT02436759
View directory record Official record
Conditions
Acquired Blepharoptosis
Interventions
RVL-1201, RVL-1201 Vehicle Placebo
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Artesia, California • Newport Beach, California • Rancho Cordova, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

NCT04091646
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Roflumilast Foam 0.3%, Vehicle foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Fremont, California • Santa Monica, California • Coral Gables, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects

NCT05525468
View directory record Official record
Conditions
Healthy
Interventions
TDM-180935, Placebo
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 27, 2026, 4:35 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

NCT05966493
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
lufepirsen high dose, Vehicle, lufepirsen low dose
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
2 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Dothan, Alabama • Petaluma, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

NCT02793817
View directory record Official record
Conditions
Post Surgical Ocular Inflammation and Pain
Interventions
KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Chandler, Arizona • Phoenix, Arizona • Artesia, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 27, 2026, 4:35 PM EDT
Terminated Phase 3 Interventional

Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

NCT04962139
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers
Interventions
ON101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Mesa, Arizona • Carlsbad, California • Castro Valley, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

NCT05190770
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV
Interventions
Triamcinolone Acetonide, Oleogel-S10
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

NCT06742957
View directory record Official record
Conditions
Plaque Type Psorisis
Interventions
Tapinarof Cream 1%, VTAMA®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
26
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Dublin, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 27, 2026, 4:35 PM EDT
Terminated Phase 2 Interventional

A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis

NCT00381602
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
GHRP-1/AG 70 mg depot in ESRD, Placebo
Drug · Other
Lead sponsor
QLT Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
New Orleans, Louisiana • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 1 Interventional

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

NCT06733402
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 27, 2026, 4:35 PM EDT
Terminated Not applicable Interventional Results available

Antipsychotic Effects of Oxytocin

NCT01621737
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Irvine, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Assessment of LBR-101 In Chronic Migraine

NCT02021773
View directory record Official record
Conditions
Chronic Migraine
Interventions
LBR-101 High Dose, LBR-101 Low Dose, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 27, 2026, 4:35 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

NCT02045901
View directory record Official record
Conditions
Morning Sickness
Interventions
Diclegis, Placebo (Sugar Pill)
Drug
Lead sponsor
Duchesnay Inc.
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Norwalk, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 27, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.

NCT04086823
View directory record Official record
Conditions
Submental Fat
Interventions
RZL-012, Placebo
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 27, 2026, 4:35 PM EDT